{"Clinical Trial ID": "NCT00703326", "Intervention": ["INTERVENTION 1:", "- Ramucirumab (IMC-1121B) + Docetaxel", "Ramucirumab (IMC-1121B) is administered at a dose of 10 milligrams per kilogram (mg/kg) as an intravenous infusion of one hour on day 1 of each 21-day cycle.", "Docetaxel is administered at a dose of 75 milligrams per square metre (mg/m2) as an intravenous infusion of one hour on day 1 of each 21-day cycle.", "INTERVENTION 2:", "Placebo + Docetaxel", "A placebo comparator for ramucirumab (IMC-1121B) administered at a dose of 10 mg/kg as an intravenous infusion of one hour on day 1 of each 21-day cycle.", "Docetaxel is administered at a dose of 75 milligrams per square metre (mg/m2) as an intravenous infusion of one hour on day 1 of each 21-day cycle."], "Eligibility": ["Incorporation criteria:", "The participant is able to provide signed informed consent", "The participant is a woman and is 18 years of age or older if required by local laws or regulations.", "The participant has a breast adenocarcinoma confirmed by histology or cytologically which is now metastatic or locally-recurrent and inoperative with curative intent. Everything should be done to make paraffin tissues or slides from the diagnostic biopsy or surgical sample available for confirmation of diagnosis.", "The participant has a measurable and/or non-measurable illness", "The primary and/or metastatic tumour of the participants is the receptor 2 (HER2)-negative human epidermal growth factor by in situ fluorescence hybridization (FISH) or chromogenic in situ hybridization (CISH) or overexpression 0, 1+ by immunohistochemistry (IHC)", "The participant did not receive prior chemotherapy for metastatic or locally recurrent and inoperative breast cancer", "\u2022 Participant completed (neo) taxane adjuvant treatment at least 6 months prior to randomization", "\u2022 Participant completed (neo) biological treatment with at least 6 weeks prior to randomization", "The participant completed all prior radiotherapy with curative intent 3 weeks prior to randomization", "The participant may have received prior hormonal treatment for breast cancer in the adjuvant (neo) and/or metastatic setting 2 weeks prior to randomization", "The participant's left ventricular ejection fraction is within normal institutional ranges", "The participant is resolved in the first year by the National Cancer Institute Common Terminological Criteria for Adverse Events, version 3 (NCI-CTCAE v 3.0) of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy or hormonal treatment, except peripheral neuropathy that must have resolved until the second year.", "The participant has a performance status of the Eastern Cooperative Oncology Group (ECOG) of 0-1", "The participant may comply with protocol schedules and testing.", "The participant has adequate haematological functions [absolute neutrophil count (NAC) 1500 cells/microlitre (mcL), hemoglobin 9 grams/deciliter (g/dL), platelets 100,000 cells/mcL and 850,000 cells/mcL]", "The participant has adequate hepatic function [bilirubin within normal limits (WNL), aspartate transaminase (AST) and alanine transaminase (ALT) 2.5 times the upper limit of normal (ULN), or 5.0 times the ULN if the elevation of the transaminase is due to hepatic metastases, and alkaline phosphatase 5.0 times the ULN]", "The serum creatinine is 1.5 x ULN. If serum creatinine is greater than 1.5 x ULN, the calculated creatinine clearance should be > 40 millilitres/minute (mL/min)", "The urinary protein of the participant is 1+ on the baguette or routine urine analysis (UA); if the urine protein 2+, a 24-hour urine collection should demonstrate < 1000 milligrams (mg) of protein within 24 hours to allow participation in the study", "The participant must have an adequate coagulation function as defined by the International Standardized Report (INR) 1.5 and a part-time thromboplastin (TPT) 1.5 X ULN if he or she is not receiving anticoagulation therapy. Participants on full-dose anticoagulation should have a stable dose of oral anticoagulant or low-weight molecular heparin and should have an INR of 2 to 3 on warfarin and no active bleeding (defined as within 14 days of randomization) or a pathological condition with a high risk of bleeding (such as a tumour involving known major vessels or varicose veins).", "Women of childbearing potential must apply adequate contraception in the opinion of the investigator", "The participant did not receive prior biological treatment for metastatic or locally recurrent and inoperative breast cancer", "- Exclusion criteria:", "A participant with a history of malignancy is eligible provided that she has been free from disease for > 3 years.", "The participant has a known sensitivity to docetaxel or other polysorbate 80 formulations", "The participant has known sensitivity to agents of similar biological composition such as ramucirumab or other agents that specifically target vascular endothelial growth factor (VEGF)", "The participant has a history of chronic diarrhoeal disease within 6 months of randomization.", "The participant received irradiation in an important area of the bone marrow, defined as > 25% of the bone marrow (such as pelvic or abdominal radiation) within 30 days prior to randomization.", "The participant participated in clinical trials of experimental agents within 4 weeks of randomization.", "The participant has a history of hereditary or acquired bleeding or uncontrolled thrombotic disorders.", "The participant has high-risk active bleeding (e.g. gastric ulcers or gastric varicose veins) within 14 days prior to randomization.", "The participant has a permanent or active infection requiring antibiotic, antifungal or antiviral parenteral therapy", "The participant has uncontrolled hypertension, symptomatic congestive heart failure, unstable breast angina, symptomatic or poorly controlled cardiac arrhythmia, psychiatric/social disorders or any other serious uncontrolled medical condition in the opinion of the investigator.", "The participant has brain metastases, uncontrolled spinal cord compression, or carcinoma meningitis, or new signs of brain or leptomenal disease", "The participant experienced an infection with human immunodeficiency virus or an acquired immunodeficiency syndrome-related disease.", "The participant has pulmonary lymphangitic impairment that results in pulmonary dysfunction requiring active treatment, including the use of oxygen.", "The participant is pregnant or breast-feeding"], "Results": ["Performance measures:", "- Progression-free survival (PFS)", "The PFS was defined as the time between randomization and the first evidence of progression as defined by the Criteria for the Assessment of Response in Solid Tumours (RECIST v1.0) or the death of any cause; by the investigator's assessment Progressive disease (PD) was defined as an increase of at least 20% in the sum of the longest diameter of the target lesions taking as a reference the smallest sum of the longest diameter since the beginning, progression in non-target lesions or the occurrence of one or more new lesions.", "Time frame: randomization to disease progression or death or to the data threshold of March 31, 2013 (up to 56 months)", "Results 1:", "Title of arm/group: Ramucirumab (IMC-1121B) + Docetaxel", "Ramucirumab (IMC-1121B) is administered at a dose of 10 milligrams per kilogram (mg/kg) as an intravenous infusion of one hour on day 1 of each 21-day cycle.", "Docetaxel is administered at a dose of 75 milligrams per square metre (mg/m) as an intravenous infusion of one hour on day 1 of each 21-day cycle.", "Total number of participants analysed: 759", "Median (95% confidence interval)", "Unit of measure: month 9.5 (8.3 to 9.8)", "Results 2:", "Title of the arm/group: Placebo + Docetaxel", "Description of the arm/group: placebo comparator for ramucirumab (IMC-1121B) administered at a dose of 10 mg/kg intravenous infusion for one hour to day 1 of each 21-day cycle.", "Docetaxel is administered at a dose of 75 milligrams per square metre (mg/m) as an intravenous infusion of one hour on day 1 of each 21-day cycle.", "Total number of participants analysed: 385", "Median (95% confidence interval)", "Unit of measure: month 8.2 (7.1 to 8.5)"], "Adverse Events": ["Undesirable Events 1:", "Total: 285/752 (37.90 per cent)", "Anemia 2/752 (0.27%)", "Disseminate intravascular coagulation 2/752 (0.27%)", "Febrile neutropenia 51/752 (6.78%)", "- Neutropenia 47/752 (6.25%)", "Thrombocytopenia 2/752 (0.27%)", "Atrial fibrillation 1/752 (0.13%)", "Atrial stem 0/752 (0.00 %)", "Congestive heart failure 1/752 (0.13%)", "- Left ventricular dysfunction 0/752 (0.00 %)", "Adverse Events 2:", "Total: 117/382 (30.63 per cent)", "Anemia 3/382 (0.79%)", "Disseminate intravascular coagulation 0/382 (0.00 %)", "- Febrile neutropenia 11/382 (2.88 per cent)", "Neutropenia 20/382 (5.24%)", "Thrombocytopenia 0/382 (0.00 %)", "Atrial fibrillation 1/382 (0.26%)", "1/382 (0.26%)", "- Congestive heart failure 0/382 (0.00 %)", "Left ventricular dysfunction 1/382 (0.26%)"]}